SubHero Banner

Rinvoq® (upadacitinib) – New indication

On January 14, 2022, AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the  treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to  severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug  products, including biologics, or when use of those therapies are inadvisable.

Download PDF